ResultsIQ › Latest results › Fredun Pharmaceuticals Limited
Fredun Pharmaceuticals Limited strategy deck summary
NSE: FREDUN · BSE: 539730
Strategy deck of 10 Jun 2025, summarised by AI from the filing.
Fredun Pharmaceuticals FY25 total income ₹456.3 cr, EBITDA ₹55.1 cr, PAT ₹20.8 cr; Freossi equipment commissioning by Q2 FY26.
Key takeaways
- Change EBITDA margin improved to 12.1% in FY25 from 11.1% in FY24
- Driver Expansion in pet care, new-age products, and government contracts
Fredun Pharmaceuticals Limited earnings call, investor presentation and press release summaries
- Q1 FY27: Earnings call (13 Aug 2026)
- Q4 FY26: Earnings call (10 Jun 2026)
- Q3 FY26: Earnings call (12 Feb 2026)
- Q2 FY26: Earnings call (11 Nov 2025)
- Q1 FY26: Earnings call (1 Aug 2025)
- Other events: Call transcript (6 Jun 2026), Strategy deck (10 Jun 2025), Strategy deck (10 Jun 2025)
Figures from the company's filings with NSE and BSE. Not investment advice.